Cancer Genomics addresses how recent technological advances in genomics are shaping how we diagnose and treat cancer. Built on the historical context of cancer genetics over the past 30 years, the book provides a snapshot of the current issues and state-of-the-art technologies used in cancer genomics. Subsequent chapters highlight how these approaches have informed our understanding of hereditary cancer syndromes and the diagnosis, treatment and outcome in a variety of adult and pediatric solid tumors and hematologic malignancies. The dramatic increase in cancer genomics research and ever-increasing availability of genomic testing are not without significant ethical issues, which are addressed in the context of the return of research results and the legal considerations underlying the commercialization of genomic discoveries. Finally, the book concludes with "Future Directions", examining the next great challenges to face the field of cancer genomics, namely the contribution of non-coding RNAs to disease pathogenesis and the interaction of the human genome with the environment. Tools such as sidebars, key concept summaries, a glossary, and acronym and abbreviation definitions make this book highly accessible to researchers from several fields associated with cancer genomics. Contributions from thought leaders provide valuable historical perspective to relate the advances in the field to current technologies and literature.
Assembled in an accessible format specifically designed for the non-expert, this book provides the clinical oncologist, early career practitioner, and trainee with an essential understanding of the molecular and genetic basis of cancer and ...
In the light of a rapidly evolving field of breast cancer genomics, this chapter highlights key standard and upcoming approaches for diagnosis, prognosis and treatment and discusses the feasibility of genome-oriented personalized treatments ...
The vast amount of genomic data being produced by the research community is becoming readily accessible to biomedical researchers and clinicians to apply to their cancer(s) of interest.
Penney KL, Sinnott JA, Fall K, et al. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol. 2011;29:2391–2396. Baca SC, Prandi D, Lawrence MS, et al. Punctuated evolution of prostate cancer genomes.
Potts MB, Cameron S. Cell lineage and cell death: Caenorhabditis elegans and cancer research. Nat Rev Cancer. 2011;11:50–58. Rudrapatna VA, Cagan RL, Das TK. Drosophila cancer models. Dev Dyn. 2012;241:107–118.
We describe past, current and upcoming sequencing technologies and the application of second-generation sequencing technologies in cancer genomics.
The book concludes with a chapter on the limitations and cost-effectiveness of NGS in CRC. Given its scope, the book will appeal to all those interested in learning about the potential of NGS in advancing CRC research and patient care.
Through this book, students, researchers and oncologists will obtain a comprehensive picture of what the first ten years of cancer genomics have revealed.
The number of people diagnosed with cancer each year will almost double to 21 million cases worldwide by 2030 because of the aging population.
This book guides the reader through methods in patient sample acquisition, the establishment of data generation and analysis pipelines, data storage and dissemination, quality control, auditing, and reporting.